Jacobson Pharma's profit up despite revenue dip

For the six months ended September 30, 2025, Jacobson Pharma reported total revenue of HK$766.6m, a 5.4% decrease from HK$810.0m in the previous interim period, primarily due to an early conclusion of the flu season. Despite this, profit attributable to equity shareholders of the company increased by 1.2% to HK$142.0m, up from HK$140.3m. Basic and diluted earnings per share also saw a slight rise to HK7.12 cents from HK7.07 cents.

The improvement in profit was largely driven by a HK$7.6m decrease in finance costs and a HK$2.9m heightened share of profits from associates, alongside reduced income tax. Gross profit for the period was HK$337.8m, with a gross profit margin of 44.1%. Total assets stood at HK$3,527.7m, a 3.2% decrease from March 31, 2025, while total liabilities increased by 8.7% to HK$1,269.1m.

The company declared an interim dividend of HK4.25 cents per share for the period, totaling approximately HK$85.0m. Strategically, the group expanded its R&D pipeline with 10 new items and granted registration approval for 11 new products, enhancing its market positioning.